Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale
Open Access
- 13 April 2026
- journal article
- Published by BMJ in Stroke and Vascular Neurology
Abstract
Background: The TRACE III trial showed that for patients with large arterial occlusion presenting 4.5–24 hours of symptom occurrence and a salvageable penumbra on perfusion imaging, intravenous tenecteplase (TNK) thrombolysis is safe and can significantly improve patient outcomes in cases where endovascular thrombectomy is not feasible. However, it is currently unknown whether intravenous TNK thrombolysis beyond 4.5 hours can improve the outcomes of subjects with distal medium vessel occlusion (MeVO). Objective: To determine the safety and effectiveness of extended window TNK thrombolysis for MeVO stroke. Methods and design: Extending the Time Window for Intravenous TNK in Patients with Distal Medium Vessel Occlusions Stroke (TNK-MeVO) is a prospective, randomised, controlled, multicentre and open-label study with blinded outcome assessment. Up to 560 eligible subjects will be randomised 1:1 to receive TNK thrombolysis or standard medical management in over 40 comprehensive stroke centres across China. Outcomes: The primary endpoint is the rates of modified Rankin Scale score of 0–1 at 90 days. Safety endpoints include symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days. Conclusions: TNK-MeVO trial is designed to provide robust evidence on whether TNK thrombolysis is safe and effective for acute MeVO stroke presenting 4.5–24 hours of symptom onset. Trial registration number: NCT06559436 .Keywords
Funding Information
- Clinical and Translational Research Project of Anhui Province (20247b10020142)
This publication has 24 references indexed in Scilit:
- Endovascular treatment of distal arterial occlusions: a more distant reality than ever?The Lancet Neurology, 2025
- StrokeThe Lancet, 2024
- Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trialThe Lancet, 2023
- Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trialThe Lancet, 2023
- Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trialThe Lancet Neurology, 2022
- Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trialThe Lancet, 2022
- MRI-Guided Thrombolysis for Stroke with Unknown Time of OnsetNew England Journal of Medicine, 2018
- Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion ImagingNew England Journal of Medicine, 2018
- Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and InfarctNew England Journal of Medicine, 2018
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007